Company intelligence / Profile preview

Iroko Pharmaceuticals, LLC

Philadelphia, Pennsylvania, United Statesiroko.com ↗

Ownership: Private
Employees: ~42
Development stage: Other

Overview

Iroko Pharmaceuticals has successfully developed and received FDA approval for multiple lower dose NSAID products using their proprietary SoluMatrix technology, including ZORVOLEX (diclofenac) in October 2013, TIVORBEX (indomethacin) in February 2014, and VIVLODEX (meloxicam) in October 2015[1][9].

Therapeutic areas: ImmunologyCardiovascularRheumatology
Modalities: Small moleculesNSAIDs (Non-Steroidal Anti-inflammatory Drugs)
Industry: Biotech

Beyond the preview

Go deeper on Iroko Pharmaceuticals, LLC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Iroko Pharmaceuticals, LLC.